RRC ID |
73099
|
Author |
Deng H, Lei Q, Wang C, Wang Z, Chen H, Wang G, Yang N, Huang D, Yu Q, Yao M, Xiao X, Zhu G, Cheng C, Li Y, Li F, Tian P, Li W.
|
Title |
A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations.
|
Journal |
Nat Commun
|
Abstract |
Therapeutic responses of non-small cell lung cancer (NSCLC) to epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs) are known to be associated with EGFR mutations. However, a proportion of NSCLCs carrying EGFR mutations still progress on EGFR-TKI underlining the imperfect correlation. Structure-function-based approaches have recently been reported to perform better in retrospectively predicting patient outcomes following EGFR-TKI treatment than exon-based method. Here, we develop a multicolor fluorescence-activated cell sorting (FACS) with an EGFR-TKI-based fluorogenic probe (HX103) to profile active-EGFR in tumors. HX103-based FACS shows an overall agreement with gene mutations of 82.6%, sensitivity of 81.8% and specificity of 83.3% for discriminating EGFR-activating mutations from wild-type in surgical specimens from NSCLC patients. We then translate HX103 to the clinical studies for prediction of EGFR-TKI sensitivity. When integrating computed tomography imaging with HX103-based FACS, we find a high correlation between EGFR-TKI therapy response and probe labeling. These studies demonstrate HX103-based FACS provides a high predictive performance for response to EGFR-TKI, suggesting the potential utility of an EGFR-TKI-based probe in precision medicine trials to stratify NSCLC patients for EGFR-TKI treatment.
|
Volume |
13(1)
|
Pages |
6944
|
Published |
2022-11-14
|
DOI |
10.1038/s41467-022-34627-5
|
PII |
10.1038/s41467-022-34627-5
|
PMID |
36376325
|
PMC |
PMC9663578
|
MeSH |
Carcinoma, Non-Small-Cell Lung* / diagnostic imaging
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
ErbB Receptors / genetics
Humans
Lung Neoplasms* / diagnostic imaging
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation
Protein Kinase Inhibitors / adverse effects
Retrospective Studies
|
IF |
12.121
|
Resource |
Human and Animal Cells |
PC-9(RCB4455)
Jurkat(RCB3052) |